Abstract
Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.
Competing Interest Statement
TW serves on advisory boards for MSD (Merck) Sharp & Dohme.
Clinical Trial
NCT02946346
Clinical Protocols
https://bmjopen.bmj.com/content/9/6/e025129
Funding Statement
This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [grant agreement No 648963 to SA].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PAPCLEAR trial is promoted by the Centre Hospitalier Universitaire de Montpellier and has been approved by the Comite de Protection des Personnes (CPP) Sud Mediterranee I on 11 May 2016 (CPP number 16 42, reference number ID RCB 2016-A00712-49); by the Comite Consultatif sur le Traitement de l'Information en matiere de Recherche dans le domaine de la Sante on 12 July 2016 (reference number 16.504); and by the Commission Nationale Informatique et Libertes on 16 December 2016 (reference number MMS/ABD/AR1612278, decision number DR-2016-488). This trial was authorised by the Agence Nationale de Securite du Medicament et des Produits de Sante on 20 July 2016 (reference 20160072000007).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data analysed in the article will be available with the published version of the article.
